Division of HIV/AIDS at SFGH

Phone: (415) 476-4082

Location(s): Africa; Kenya; Uganda; Tanzania; Zambia; Zimbabwe; South Africa; Ivory Coast; Mali; India; Viet Nam; France; Italy; Russia; Spain; United Kingdom; Argentina; Brazil; Peru; Puerto Rico; United States; Australia

Description

The HIV/AIDS Division is globally engaged in research and education around the world. They have established partnerships that lead work to address the most pressing issues of the HIV epidemic in resource limited settings. They are committed and actively training the next generation of HIV researchers from countries most affected by HIV. Ongoing projects span from understanding disease pathogenesis to epidemiology to treatment to models of care delivery. The HIV/AIDS DIvision co-directs the Makerere University–UCSF research collaboration which has enrolled over 20,000 patients on clinical studies evaluating HIV, TB, malaria, and nutrition.

Major components of that collaboration include:

  • ICEMR/PRISM  (International Center of Excellence for Malaria Research /Program for Resistance, Immunology, Surveillance and Modeling of Malaria in Uganda): a global network of independent research centers in malaria-endemic settings to provide knowledge, tools, and evidence-based strategies to support researchers working in a variety of settings, especially within governments and healthcare institutions. 
  • SEARCH (Sustainable East Africa Research on Community Health): evaluating the health, education and economic outcomes of novel community based interventions in a "test and treat" approach that includes HIV as well as non-communicable diseases such as hypertension.
  • UMSP (Uganda Malaria Surveillance Project): a multi-site surveillance system for monitoring antimalarial drug efficacy and safety, malaria related morbidity and mortality and building capacity for facility based management of malaria.

Archived Projects: 233

Project Investigator Topics Location Start End
Delete link
Immediate Salvage Therapy w/ Combination ART plus T-20 vs. A 16 Week Structured Treatment Interruption Followed by Combination Therapy plus T-20 Steven G. Deeks, MD HIV/AIDS, Pharmacology and Drug Treatment United States
PCP OPW Specimens Laurence Huang, MD Opportunistic Infection Uganda
Interruption of Enfuvirtide in Patients Experiencing an Incomplete Virologic Response to Enfuvirtide-Based Combination Antiretroviral Regimen Steven G. Deeks, MD HIV/AIDS, Pharmacology and Drug Treatment United States
Crossing Boundaries: Continuity of Medical Care for Incarcerated Adults Jacqueline P. Tulsky, MD HIV/AIDS, Access or Barriers to Care United States
International AIDS Research and Prevention Diane V. Havlir, MD HIV/AIDS Uganda
Adolescent Modules - AETC Web Site Susan C. Coffey, MD HIV/AIDS, Systematic Reviews and Guideline Development, Training and Capacity Building United States
The Biologic Determinants of HIV Transmission / HIV Applied Research Frederick M. Hecht, MD HIV/AIDS United States
VA HIV Website Susan C. Coffey, MD HIV/AIDS United States
UCSF HIV/AIDS Management Training Programs Diane V. Havlir, MD HIV/AIDS, Training and Capacity Building United States
Primary Care Services- Non Severe Need - Ward 86 HIV/AIDS United States
Treatment Intensification for Drug-Resistant HIV Steven G. Deeks, MD HIV/AIDS United States
The Use of Nelfinavir During Acute or Early HIV Infection - Safety, Tolerability, Durablilty and Resistance HIV/AIDS, Pharmacology and Drug Treatment United States
A Clinical Trial of DOT for HAART in Jailed Drug Users / AIDS Related Jacqueline P. Tulsky, MD HIV/AIDS United States
Enfuvirtide Intensification for Multi-Drug Resistant HIV Steven G. Deeks, MD Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Pharmacology and Drug Treatment United States
Determination of Reyataz (Atazanavir Sulfate) Levels in Hair: A New Assay and Possible Predictor for Long-Term Virologic Outcome Monica Gandhi, MD, MPH Implementation and Behavioral Science, Treatment Adherence United States
Adult AIDS Clinical Trials Unit (AACTU) Diane V. Havlir, MD HIV/AIDS United States
Enfuvirtide Treatment Intensification in Patients with Multi-Drug Resistant HIV Steven G. Deeks, MD HIV/AIDS, Pharmacology and Drug Treatment United States
T Regulatory Cells and T Cell Activation in HIV Disease Steven G. Deeks, MD HIV/AIDS, Immunology United States
Molecular Epidemiology of Human P. Carinii Pneumonia Laurence Huang, MD United States
Positive Health Access to Service and Treatment (PHAST) HIV/AIDS, Engagement in Care United States
UMDNJ / WHO Dept. of HIV/AIDS "Development of an Annotated Inventory of PMTCT Tools and Guidelines" Susan C. Coffey, MD HIV/AIDS, Women's Health, Pediatrics, Newborn and Infant Health Kenya
HIV Health Services - Program Database Services HIV/AIDS United States
HIV Controllers: A Potential Model for HIV Eradication Steven G. Deeks, MD HIV/AIDS, Immunology United States
Drugs, Gender and Healthcare Use among HIV+ Homeless Elise Riley, PhD HIV/AIDS, Neurology and Mental Health, Substance Abuse United States
Positive Health Access to Service and Treatment (PHAST) HIV/AIDS, Access or Barriers to Care, Health Systems Strengthening United States
San Francisco National Clinical Trial Center, ESPIRIT Steven G. Deeks, MD HIV/AIDS, Pharmacology and Drug Treatment Morocco; Japan; Singapore; Thailand; Israel; Austria; Belgium; Denmark; France; Germany; Ireland; Italy; Netherlands; Norway; Poland; Portugal; Spain; United Kingdom; Argentina; Brazil; Canada; Australia
Evaluation of Adherence to National Guidelines on HIV Prevention for HIV-infected Patients in Clinical Care in Nine US Clinics Who Serve Men Who Have Sex with Men (MSM) HIV/AIDS, Systematic Reviews and Guideline Development, Treatment Adherence, Health Systems Strengthening United States
HIV Treatment Training for Clinical Setting HIV/AIDS, Residencies, Fellowships, and Postdoctoral Training United States
Adolescent Modules - AETC Web Site (Cont.) Susan C. Coffey, MD HIV/AIDS, Systematic Reviews and Guideline Development, Training and Capacity Building United States
HIV Vaccine Trials Network - Laboratory Personnel Support Teri Liegler, PhD Immunology Malawi; Mozambique; South Africa; China; Peru
Valganciclovir to Reduce T Cell Activation in HIV Infection Peter W. Hunt, MD HIV/AIDS, Drug and Diagnostics Development, Immunology United States
Women, Children, and HIV Website (DBS) Susan C. Coffey, MD HIV/AIDS, Women's Health, Pediatrics, Newborn and Infant Health United States
Therapeutic Strategies for HIV Disease Diane V. Havlir, MD HIV/AIDS Uganda
UMDNJ / "Tanzania PMTCT Training Package" Susan C. Coffey, MD HIV/AIDS, Women's Health, Pediatrics, Training and Capacity Building Tanzania
A Probe to Evaluate the Safety, Tolerability & Immunogenicity of the MRK Adenovirus Serotype 5 Vector Human Immunodeficiency Virus Type 1 gag Vaccine in HIV-1 Infected Anne F. Luetkemeyer, MD HIV/AIDS United States
Abbott Preceptorship HIV/AIDS United States
Training in HIV Primary Care - Uganda Clinicians Diane V. Havlir, MD HIV/AIDS, Training and Capacity Building Uganda
HIV/TB in Uganda: Punctuated Antiretroviral Therapy Diane V. Havlir, MD HIV/AIDS, Tuberculosis Uganda; South Africa
International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-Sulfamethoxazole for Treatment of Acute Pneumocystis jiroveci Pneumnia (PCP) in Patients with HIV/AIDS Laurence Huang, MD HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment United States
Elite Controllers Steven G. Deeks, MD HIV/AIDS, Immunology, Genetics United States
Environment and HIV Risks among Unstably Housed Women Elise Riley, PhD HIV/AIDS, Women's Health, Access or Barriers to Care United States
A Pilot Study of an Integrated Diet/Exercise and Stress-Reduction Meditation Intervention for Obesity with Metabolic Syndrome Features Frederick M. Hecht, MD Diet, Exercise, and Obesity United States
UCSF-FIND Uganda Project Laurence Huang, MD Tuberculosis, Drug and Diagnostics Development Uganda
A phase III trial to investigate the efficacy, tolerability & safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects w/ limited to no treatment options Anne F. Luetkemeyer, MD HIV/AIDS, Pharmacology and Drug Treatment United States
Ward 86 Outpatient Services/Perinatal Services HIV/AIDS, Patient and Peer Education United States
Administering Buprenorphine in the San Francisco County Jail Jacqueline P. Tulsky, MD Access or Barriers to Care, Substance Abuse United States
Clinical Care Response Team Introduction of Antiretroviral Therapy in Elizabeth Glaser Pediatric AIDS Foundation Sites Diane V. Havlir, MD HIV/AIDS, Engagement in Care, Health Systems Strengthening, Training and Capacity Building Uganda
The Influence of Pharmacy-Based Syringe Disposal on Unsafe Syringe Discard Among Injection Drug Users in California Elise Riley, PhD Substance Abuse, Risk Reduction and Prevention United States
Probing Below the Surface: Development of a Molecular Diagnostic Assay to Detect Emergent Viral Escape Variants Teri Liegler, PhD HIV/AIDS, Drug and Diagnostics Development United States
Treatment of Acute Hepatitis C Virus in HIV Co-Infection Sexually Transmitted Infections (STIs), HIV/AIDS United States
PCP OPW Specimens/Uganda Project Support Laurence Huang, MD Infectious Disease, HIV/AIDS, Opportunistic Infection Uganda
Long Term Follow-Up of Patients Enrolled in Clinical Trials (#A-9602, A-9604, A-9801) Using Retroviral Gene Based Therapies / AIDS related research Steven G. Deeks, MD HIV/AIDS United States
Ultra-Low Viral Detection Using the Abbott RealTime HIV-1 Assay Teri Liegler, PhD HIV/AIDS, Drug and Diagnostics Development United States
HIV/TB in Uganda: Punctuated Antiretroviral Therapy Diane V. Havlir, MD HIV/AIDS, Tuberculosis Uganda; South Africa
Chronic Care HIV/AIDS Multi-Disciplinary Program (CCHAMP) HIV/AIDS United States
Tibotec TMC125-C214: Early Access of TMC125 in Combination with Other Antiretrovirals in Treatment-Experienced HIV-1 Infected Subjects with Limited Treatment 0ptions Anne F. Luetkemeyer, MD HIV/AIDS, Pharmacology and Drug Treatment United States
She's Living Positive Health Fair HIV/AIDS, Patient and Peer Education United States
The Determinants of T Cell Activation in HIV Infection Peter W. Hunt, MD HIV/AIDS United States
Women, Children, and HIV Website Susan C. Coffey, MD HIV/AIDS, Women's Health, Patient and Peer Education United States
Ward 86 Outpatient Services/Perinatal Services HIV/AIDS, Newborn and Infant Health United States
Training in HIV Translational Research Diane V. Havlir, MD HIV/AIDS, Training and Capacity Building United States
Atripla Adherence and Resistance Relationships [I] Steven G. Deeks, MD HIV/AIDS, Treatment Adherence United States
Atripla Adherence and Resistance Relationships [II] Steven G. Deeks, MD HIV/AIDS, Treatment Adherence United States
ADS-TCAD-P0206: TCAD Oral for Treatment of Influenza A Diane V. Havlir, MD Infectious Disease, HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment United States
Raltegravir Intensification in Antiretroviral-Treated Patients Exhibiting a Suboptimal CD4+T Cell Response Steven G. Deeks, MD HIV/AIDS, Immunology United States
Clinical Studies of Interactions Between HIV and Malaria Diane V. Havlir, MD HIV/AIDS, Malaria Uganda
HIV-HEP C Website Maintenance Services Susan C. Coffey, MD Infectious Disease, HIV/AIDS, Patient and Peer Education United States
Entecavir Intensification for HIV-HBV Coinfected subjects with persistent HBV viremia Anne F. Luetkemeyer, MD Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment United States
Chronic Care HIV/AIDS Multidisciplinary Program (CCHAMP) HIV/AIDS, Neurology and Mental Health United States
Innate Immune Response Genetics and T cell Activation in Treated HIV Infection Peter W. Hunt, MD HIV/AIDS Uganda
Innate Effector Function and HIV-1 Control Steven G. Deeks, MD HIV/AIDS, Immunology United States
Master Agreement: International Network for Strategic Initiatives in Global HIV Trials/ICR INSIGHT Steven G. Deeks, MD HIV/AIDS Uganda; South Africa; Mali; Nigeria; China; Malaysia; Thailand; Mexico; Argentina; Brazil; Chile; Peru; Uruguay
Task Order Supplement to A5267 Diane V. Havlir, MD HIV/AIDS, Tuberculosis, Pharmacology and Drug Treatment United States
Task Order # 7: Supplement to SSS A5254 Diane V. Havlir, MD HIV/AIDS, Opportunistic Infection, Oral Health United States
International Network for Strategic Initiatives in Global HIV Trials/ ICR INSIGHT Steven G. Deeks, MD HIV/AIDS, Drug and Diagnostics Development South Africa; Mali; Brazil; Peru
Task Order # 6: Supplement to SSS A5257 Diane V. Havlir, MD HIV/AIDS United States
Inflammatory and Clinical Consequences of Low-Level Viremia in HIV-1 Infected Patients Hiroyu Hatano, MD, MHS HIV/AIDS, Immunology United States
Ultrasensitive Monitoring of HIV-1 Drug Resistance Reversion Following Transmission with Drug Resistant Virus Teri Liegler, PhD HIV/AIDS, Pharmacology and Drug Treatment, Women's Health, Newborn and Infant Health Botswana
The Impact of Food Insecurity on HIV Outcomes and Sexual Risk Behavior in Uganda Sheri D. Weiser, MD HIV/AIDS, Malnutrition, Micronutrients, Food Insecurity, Risk Reduction and Prevention Uganda
International HIV-Associated Opportunistic Pneumonias (IHOP) Study Laurence Huang, MD HIV/AIDS Uganda; United Kingdom; United States
HIV and Lung Complications in the ART Era: Focus on Obstructive Lung Disease Laurence Huang, MD HIV/AIDS, Chronic Respiratory Disease United States
HIV Entry Inhibitors: A New Therapeutic Option Steven G. Deeks, MD HIV/AIDS, Immunology United States
HPV Epidemiology and Response to Screening (HEARTS) Elise Riley, PhD United States
FIND Xpert MTB assay collaboration at Mulago Hospital Laurence Huang, MD Tuberculosis Uganda
TO#5 ACTG-Clinical Research Site - Community Health Promoter Position Diane V. Havlir, MD HIV/AIDS United States
UCSF/Ragon Collaboration on HIV "Elite" Controllers Steven G. Deeks, MD HIV/AIDS, Drug and Diagnostics Development, Immunology, Genetics United States
Sexual Harm Reduction for HIV+ Gay Men (Prevention with Positives) HIV/AIDS, Risk Reduction and Prevention United States
Clinical Care Response Team Introduction of Antiretroviral Therapy in Elizabeth Glaser Pediatric AIDS Foundation Sites Diane V. Havlir, MD HIV/AIDS, Pediatrics Kenya; Uganda; Tanzania; Zimbabwe; South Africa; Ivory Coast
Family Service Networks - Centers of Excellence HIV/AIDS United States
HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART HIV/AIDS United States
HIV Emergence of Drug Resistance Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Pharmacology and Drug Treatment South Africa
Comparison of Assays to Measure Viral Reservoirs in HIV Eradication Frederick M. Hecht, MD HIV/AIDS United States
Food Insecurity: A Key Structural Barrier to HIV/AIDS Care Sheri D. Weiser, MD HIV/AIDS, Malnutrition, Micronutrients, Food Insecurity, Access or Barriers to Care, Implementation and Behavioral Science United States
Treating HIV-Infected Elite Controllers as a Model of HIV Remission Hiroyu Hatano, MD, MHS HIV/AIDS, Immunology United States
Inflammation, T Cell Senescence, and Mortality in Treated HIV Infection Peter W. Hunt, MD HIV/AIDS United States
Preventing the Establishment of Enfuvirtide-Resistance in the Latent Reservoir Steven G. Deeks, MD HIV/AIDS United States
Cepheid 077B-C: Evaluation of the Xpert® MTB/RIF Assay Anne F. Luetkemeyer, MD Tuberculosis Uganda; United States
AIDS Clinical Trials Group (ACTG) Community Health Promoter Diane V. Havlir, MD HIV/AIDS Uganda
Supplement to ATCG A5254: Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load Diane V. Havlir, MD HIV/AIDS Haiti
Characterization of Persistent HIV Viremia Frederick M. Hecht, MD HIV/AIDS United States
Virologic and Host Factors Contributing to HIV Control in Elite Controllers Hiroyu Hatano, MD, MHS HIV/AIDS United States
ACTG A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects Diane V. Havlir, MD HIV/AIDS, Tuberculosis United States
T Regulatory Cells in HIV Infection Douglas Nixon, MD, PhD HIV/AIDS United States
AIDS Clinical Trials Network (ACTG) -- Peter Hunt Task Order Peter W. Hunt, MD HIV/AIDS United States
AIDS Clinical Trials Group (ACTG) TTSG Services Diane V. Havlir, MD HIV/AIDS United States
Disulfiram to Accelerate Decay in HIV Reservoirs in ART Treated Patients Steven G. Deeks, MD HIV/AIDS United States
AIDS Research and Services at SFGH Diane V. Havlir, MD HIV/AIDS United States
Training Researchers in Clinical Integrative Medicine (TRIM) Frederick M. Hecht, MD Training and Capacity Building United States
Pfizer A4001027: Observational Phase Extension Anne F. Luetkemeyer, MD HIV/AIDS, Pharmacology and Drug Treatment United States
Metabolic Substudy of A5257, CIMT/FMD Repeat Scans (ACTG A5260s:) Anne F. Luetkemeyer, MD HIV/AIDS United States
HIV and Lung Complications in the HAART Era: Focus on Obstructive Lung Disease(l)) Laurence Huang, MD HIV/AIDS United States
Assessing Antiretroviral Exposure in Diverse Populations Monica Gandhi, MD, MPH HIV/AIDS, Pharmacology and Drug Treatment United States
HIV Pathogenesis and Immunity in Viremic Non-Progressors Peter W. Hunt, MD HIV/AIDS United States
Ryan White Title IV Program: Family Services Network HIV/AIDS United States
HIV-Specific T-cell Responses in Rectal Mucosa Peter W. Hunt, MD HIV/AIDS United States
Adherence Improvement & Measurement (AIM) System Treatment Adherence United States
The Impact of Early Antiretroviral Therapy on HIV Persistence and Inflammation Steven G. Deeks, MD HIV/AIDS, Pharmacology and Drug Treatment United States
The Impact of Early Antiretroviral Therapy on HIV Persistence and Inflammation Steven G. Deeks, MD HIV/AIDS United States
Hepatitis C Co-infection Clinic: A to T (Acute to Transplant) Sexually Transmitted Infections (STIs), HIV/AIDS United States
Determinants of HIV Transmission Frederick M. Hecht, MD HIV/AIDS, Epidemiology and Surveillance United States
Metabolic and Immuologic Effects of Meditation - Cell Aging Supplement Frederick M. Hecht, MD United States
Neurological AIDS Research Consortium Diane V. Havlir, MD HIV/AIDS United States
Administration of an ACE-Inhibitor to Decrease the Latent Reservoir Hiroyu Hatano, MD, MHS HIV/AIDS United States
Family-Based HIV Voluntary Testing and Counseling in Patients at Risk for Tuberculosis Edwin D. Charlebois, PhD HIV/AIDS, Tuberculosis, Implementation and Behavioral Science Uganda
Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naïve for Hepatitis C Infectious Disease, HIV/AIDS United States
Immunologic Determinants of CD4+ T Cell Recovery in Treated HIV+ Africans Peter W. Hunt, MD HIV/AIDS Uganda
Options Project Frederick M. Hecht, MD HIV/AIDS United States
Task Order Agreement No. CRB-DCR01-S-09-00325 Diane V. Havlir, MD Drug and Diagnostics Development United States
Mesalamine to Reduce T Cell Activation in HIV Infection Peter W. Hunt, MD HIV/AIDS, Drug and Diagnostics Development United States
The Impact of Food Insecurity on HIV Outcomes and Sexual Risk Behavior in Uganda Sheri D. Weiser, MD HIV/AIDS, Malnutrition, Micronutrients, Food Insecurity, Implementation and Behavioral Science, Risk Reduction and Prevention Uganda
Study of Three NNNRTI-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (ACTG A5257) Diane V. Havlir, MD HIV/AIDS, Pharmacology and Drug Treatment Puerto Rico
Cardiovascular, Anthropometric, and Skeletal Effects of ART Initiation with FTC/TDF plus ATV/r: Metabolic Substudy of A5257 (ACTG A5260s) Diane V. Havlir, MD HIV/AIDS United States
AIDS Clinical Trials Network (ACTG)-Deeks (Co-Vice Chair) A5296 Steven G. Deeks, MD HIV/AIDS, Noncommunicable and/or Chronic Disease, Pharmacology and Drug Treatment United States
Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects (ATCG A5262) Diane V. Havlir, MD HIV/AIDS, Pharmacology and Drug Treatment United States
Task Order A5280: A Prospective, Randomized Pilot Trial of High Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART) Diane V. Havlir, MD HIV/AIDS United States
HIV and Lung Complications in the HAART Era: Focus on Obstructive Lung Disease (ll) Laurence Huang, MD HIV/AIDS United States
AIDS Research and Services at SF General Hospital Diane V. Havlir, MD HIV/AIDS, Engagement in Care, Treatment Adherence, Risk Reduction and Prevention United States
AETC National Resource Center / AIDS Education and Training Website Susan C. Coffey, MD HIV/AIDS, Training and Capacity Building United States
Effects of Housing and HIV on Risk Behavior and Victimization of Indigent Women Elise Riley, PhD HIV/AIDS, Women's Health United States
Cardiovascular, Anthropometric, and Skeletal Effects of ART Initiation with FTC/TDF plus ATV/r: Metabolic Substudy (ACTG) A5260s Anne F. Luetkemeyer, MD HIV/AIDS United States
Treating HIV-infected Elite Controllers as a Model of HIV Remission Steven G. Deeks, MD HIV/AIDS United States
Novel Strategies to Prevent Malaria and Improve HIV Outcomes in Africa (I) Diane V. Havlir, MD HIV/AIDS, Malaria Uganda
Tobira 652-2-202 Pre-Clinical Trial Cost Agreement Anne F. Luetkemeyer, MD HIV/AIDS, Pharmacology and Drug Treatment United States
HIV and HPV Transmission across Mucosal Epithelia Sharof Tugizov, PhD HIV/AIDS United States
Task Order: R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS Steven G. Deeks, MD United States
Short-Term Disulfiram Administration to Reverse Latent HIV Infection Steven G. Deeks, MD HIV/AIDS, Pharmacology and Drug Treatment United States
Productive and Latent HIV Infection in Gut Mucosal Reservoirs Diane V. Havlir, MD HIV/AIDS United States
Patient-Oriented Research and Mentoring in Pneumocystis Laurence Huang, MD Uganda
BMS-790052 with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Peginterferon Alfa plus Mandana Khalili, MD Mexico; Argentina; Puerto Rico; Australia
HIV Persistence after Successful CCR5-Depleted Stem Cell Transplantation Steven G. Deeks, MD HIV/AIDS United States
Exploring the Bidirectional Relationship between Food Security and HIV Treatment Outcomes in a Rural Ugandan Cohort Sheri D. Weiser, MD HIV/AIDS, Malnutrition, Micronutrients, Food Insecurity, Treatment Adherence Uganda
EraMune Project Steven G. Deeks, MD United States
KAM Training United States
AIDS Clinical Trial Group (ACTG) Tuberculosis TSG Services Diane V. Havlir, MD HIV/AIDS, Tuberculosis United States
AIDS Clinical Trial Research Group (ACTG), Studies: A5306, A5254, A5298 Diane V. Havlir, MD HIV/AIDS, Opportunistic Infection, Tuberculosis, Oral Health Uganda
AIDS Clinical Trials Network (ACTG)- Peter Hunt Task Order Peter W. Hunt, MD HIV/AIDS United States
ACTG, AIDS Clinical Trials Research Group - A5289 and A5255 Anne F. Luetkemeyer, MD HIV/AIDS United States
ACTG A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and Uninfected Pulmonary Tuberculosis Suspects Diane V. Havlir, MD HIV/AIDS, Tuberculosis United States
HIV Specific T-Cell Responses in Rectal Mucosa Steven G. Deeks, MD HIV/AIDS United States
Effects of Exercise on Aging among Older Persons with HIV -- Pilot Study Frederick M. Hecht, MD HIV/AIDS, Diet, Exercise, and Obesity United States
Mesalamine to Reduce T cell Activation in HIV Infection Ma Somsouk, MD, MAS HIV/AIDS United States
Novel approaches to monitoring and utilizing adherence to HIV therapy in Africa Peter W. Hunt, MD HIV/AIDS Uganda
VX11-950-115 An Open Label, Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1) Sexually Transmitted Infections (STIs), HIV/AIDS United States
Treating HIV-Infected Elite Controllers as a Model of HIV Remission Hiroyu Hatano, MD, MHS HIV/AIDS United States
UCSF HIV Clinical Trials Unit Diane V. Havlir, MD HIV/AIDS United States
Identifying and Targeting HIV Persistence in T Cell Subsets during ART Steven G. Deeks, MD HIV/AIDS United States
Factor IX studies at UCSF for GBT Matthew Jacobson, PhD Drug and Diagnostics Development United States
Developing a Mentoring Network of Diverse Mental Health Professionals Utilizing the CNICS Platform Monica Gandhi, MD, MPH Residencies, Fellowships, and Postdoctoral Training United States
Impact of Parasitemia on the Development of Cellular Immune Responses to Malaria Prasanna Jagannathan, MD Malaria Uganda
Novel Strategies to Prevent Malaria and Improve HIV Outcomes in Uganda (II) Diane V. Havlir, MD HIV/AIDS Uganda
Core B: Specimen Repository Core Steven G. Deeks, MD United States
HIV Exposure in a Sample of HESN Men Having Sex with Men Frederick M. Hecht, MD HIV/AIDS United States
IDO-induced Tryptophan Catabolism and Mortality in Treated HIV-infected Africans Peter W. Hunt, MD HIV/AIDS Uganda
Early Mortality in HIV-Infected Patients Starting Antiretroviral Therapy in Africa Elvin H. Geng, MD, MPH HIV/AIDS, Pharmacology and Drug Treatment Uganda
A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy with Genotype 1 Chronic Hepatitis C Anne F. Luetkemeyer, MD Sexually Transmitted Infections (STIs) France; Germany; Hungary; Spain; Argentina
Women, Children, and HIV Website Susan C. Coffey, MD HIV/AIDS, Women's Health, Labor and Delivery, Family Planning, Pediatrics, Newborn and Infant Health, Training and Capacity Building Kenya; Malawi; Mauritius; Mozambique; Rwanda; Seychelles; Somalia; Uganda; Tanzania; Zambia; Zimbabwe; Angola; Cameroon; Central African Republic; Chad; Botswana; Lesotho; Namibia; South Africa; Swaziland; Gambia; Ghana; Liberia; Nigeria; India; Pakistan; Sri Lanka; Singapore; Philippines; United Kingdom; Anguilla; Antigua and Barbuda; Bahamas; Barbados; Cayman Islands; Dominica; Grenada; Jamaica; Saint Kitts and Nevis; Saint Lucia; Trinidad and Tobago; U.S. Virgin Islands; Northern Mariana Islands; Australia; Marshall Islands; Palau; Papua New Guinea; Samoa; Solomon Islands; Tokelau; Tonga; Tuvalu; Vanuatu
The Biology of HIV Transmission Frederick M. Hecht, MD HIV/AIDS, Drug and Diagnostics Development United States
Task Order A5303: Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naive Patients Infected with R5-Tropic HIV-1 Diane V. Havlir, MD HIV/AIDS, Pharmacology and Drug Treatment Uganda
Promoting Health Career Opportunities for Youth: MedLink Sharad Jain, MD Health Systems Strengthening, Training and Capacity Building United States
ACTG A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects Anne F. Luetkemeyer, MD HIV/AIDS, Tuberculosis United States
Novel Strategies to Prevent Malaria and Improve HIV Outcomes in Africa (III) Diane V. Havlir, MD HIV/AIDS, Malaria Uganda
High Throughput Measurement of Envelope Gene Diversity for an HIV Incidence Assay Christopher D. Pilcher, MD HIV/AIDS, Drug and Diagnostics Development United States
Development of Specimen Repository and Evaluation of Assays for Identification of Recent HIV Infection Christopher D. Pilcher, MD HIV/AIDS South Africa
International HIV-Associated Opportunistic Pneumonias (IHOP) Study Laurence Huang, MD HIV/AIDS Uganda; United Kingdom
Feasibility of a Point-Of-Care CD4+ Test Hiroyu Hatano, MD, MHS United States
Epigenetic Regulation of HIV Latency Steven G. Deeks, MD HIV/AIDS United States
Performance Evaluation of the Bio-Rad Geenius HIV-1/2 Supplemental Assay Christopher D. Pilcher, MD HIV/AIDS, Drug and Diagnostics Development United States
DAIDS A5298 Study: A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men Anne F. Luetkemeyer, MD HIV/AIDS, Cancer/Oncology Brazil; Puerto Rico
Study of BMS-790052 plus Peg-Interferon alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with HIV and HCV Anne F. Luetkemeyer, MD HIV/AIDS France; Germany; Italy; Russia; Spain; United Kingdom; Argentina; Puerto Rico; Canada; Australia
Therapeutic Strategies for HIV Disease Diane V. Havlir, MD HIV/AIDS Uganda
VA HIV-HEP C Website Maintenance Services Susan C. Coffey, MD HIV/AIDS, Health Systems Strengthening, Training and Capacity Building, Patient and Peer Education United States
Optimizing Rapid and Full Engagement in Care for Persons with Newly Diagnosed HIV Katerina Christopoulos, MD, MPH HIV/AIDS, Engagement in Care United States
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Richard W. Price, MD HIV/AIDS United States
Metabolic and Immunologic Effects of Meditation Frederick M. Hecht, MD United States
Ghana: UCSF Technical Assistance to Support PEPFAR George W. Rutherford, MD HIV/AIDS, Epidemiology and Surveillance, Implementation and Behavioral Science Ghana
Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START) Diane V. Havlir, MD HIV/AIDS Uganda
Statins for Pulmonary and Cardiac Complications of Chronic HIV (The SPARC Trial) Laurence Huang, MD HIV/AIDS United States
Administration of an ACE Inhibitor to Improve Endothelial Function in Treated, HIV-infected Individuals Hiroyu Hatano, MD, MHS HIV/AIDS, Cardiovascular Disease United States
CHRP for Integrating HIV and Geriatric for People Living with HIV 50 and Over HIV/AIDS, Engagement in Care, Health Systems Strengthening United States
Family Services Network - Ryan White HIV/AIDS Program Infectious Disease, HIV/AIDS, Systematic Reviews and Guideline Development United States
Characterization of the HIV-1 Latent Reservoir in CCR5-Delta 32 Heterozygotes Steven G. Deeks, MD HIV/AIDS United States
ACE-Inhibitors to Decrease Lymphoid Fibrosis and the Size of the Latent Reservoir in Antiretroviral-Treated, HIV-infected Patients: A Randomized, Placebo-Controlled Study Hiroyu Hatano, MD, MHS HIV/AIDS, Pharmacology and Drug Treatment United States
Novel Approaches to Monitoring and Utilizing Adherence to HIV Therapy in Africa Jeffrey N. Martin, MD, MPH HIV/AIDS, Implementation and Behavioral Science, Treatment Adherence Uganda
Women's Center of Excellence HIV/AIDS, Women's Health, Engagement in Care, Treatment Adherence, Health Systems Strengthening, Patient and Peer Education United States
Data Collected through the IAVI Early Infection Cohort Study Christopher D. Pilcher, MD HIV/AIDS United States
ViiV Healthcare A4001098 Anne F. Luetkemeyer, MD United States
Specimens Related to the MU-UCSF Research Collaboration Laurence Huang, MD HIV/AIDS Uganda
Seek, Test, Treat and Retain Strategies Leveraging Mobile Health and Internet-Based Technologies Jacqueline P. Tulsky, MD United States
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Ann V. Schwartz, PhD, MPH HIV/AIDS South Africa; India; Thailand; Belgium; Ireland; Italy; Spain; United Kingdom; Brazil; Peru; Australia
HIV-Specific T-Cell Responses in Rectal Mucosa Peter W. Hunt, MD Immunology United States
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Steven G. Deeks, MD HIV/AIDS Tanzania; Zambia; Morocco; South Africa; Mali; Thailand; Greece; Argentina; Brazil; Chile; Peru
Molecular Epidemiology and Geospatial Analysis of Tuberculosis Transmission in Uganda Gabriel Chamie, MD HIV/AIDS, Tuberculosis, Epidemiology and Surveillance Uganda
Development of Potent/Selective Lipoxygenase Therapeutics against Stroke Injury Matthew Jacobson, PhD Dementia and Cognitive Impairment United States
African American Center of Excellence HIV/AIDS, Access or Barriers to Care, Stigma and Discrimination, Engagement in Care, Health Systems Strengthening, Patient and Peer Education United States
Ward 86 Outpatient Services / Perinatal Services HIV/AIDS, Women's Health, Newborn and Infant Health United States
DARE: Delaney AIDS Research Enterprise to Find a Cure Steven G. Deeks, MD HIV/AIDS Sweden; Australia
Positive Health Access to Services and Treatment (PHAST) HIV/AIDS United States
Training in HIV Translational Research Diane V. Havlir, MD Training and Capacity Building United States
Lung Microbiome in Cohorts of HIV-Infected Persons (Lung MicroCHIP) Study Laurence Huang, MD HIV/AIDS United States
Pathogenesis of Emphysema/Obstruction and the Microbiome (POEM) in HIV Laurence Huang, MD HIV/AIDS, Chronic Respiratory Disease United States
R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS Elvin H. Geng, MD, MPH HIV/AIDS, Implementation and Behavioral Science, Engagement in Care United States
GS-US-183-0130: A Phase 3, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents in the Treatment of HIV-1 Infected Subjects Anne F. Luetkemeyer, MD HIV/AIDS United States
HIV RNA and/or Antibody Confirmed Positive Plasma Christopher D. Pilcher, MD HIV/AIDS South Africa
Pathways from Food Insecurity to Health and Treatment Outcomes in Women with HIV Sheri D. Weiser, MD HIV/AIDS, Malnutrition, Micronutrients, Food Insecurity, Women's Health United States
Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention Trials Monica Gandhi, MD, MPH HIV/AIDS Uganda
Expanded HIV Testing for Disproportionately Affected Population HIV/AIDS United States
Early Antiretroviral Therapy in Resource Limited Settings in Patients with High CD4+ Cell Counts Vivek Jain, MD HIV/AIDS, Pharmacology and Drug Treatment Uganda
Immunologic Consequences of Highly Effective Antimalarial Chemoprevention Prasanna Jagannathan, MD Malaria Uganda; Zimbabwe
ACTG A5294: A Prospective, Phase III Open-Label Study of Response-Guided Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects Anne F. Luetkemeyer, MD HIV/AIDS United States
Impact of HIV-Associated Inflammation on Disease Steven G. Deeks, MD HIV/AIDS United States
Training Researchers in Clinical Integrative Medicine (TRIM) Frederick M. Hecht, MD Training and Capacity Building United States
Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination with Ribavirin and Daclatasvir for Treatment of Chronic HCV Infection with Treatment Naïve Genotypes 1, 2, 3 or 4 in Subjects Coinfected with HIV-1 Anne F. Luetkemeyer, MD HIV/AIDS United States
Master Agreement: R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS Steven G. Deeks, MD HIV/AIDS United States